Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Open access

Abstract

Background: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as ≤10% residual viable tumor (RVT), may predict improved long-term patient outcome. However, %RVT calculations were developed in the context of chemotherapy (%cRVT). An immune-related %RVT (%irRVT) has yet to be developed. Patients and methods: The first trial of neoadjuvant anti-PD-1 (nivolumab, NCT02259621) was just reported. We analyzed hematoxylin and eosin-stained slides from the post-treatment resection specimens of the 20 patients with non-small-cell lung carcinoma who underwent definitive surgery. Pretreatment tumor biopsies and preresection radiographic 'tumor' measurements were also assessed. Results: We found that the regression bed (the area of immune-mediated tumor clearance) accounts for the previously noted discrepancy between CT imaging and pathologic assessment of residual tumor. The regression bed is characterized by (i) immune activation-dense tumor infiltrating lymphocytes with macrophages and tertiary lymphoid structures; (ii) massive tumor cell death-cholesterol clefts; and (iii) tissue repair-neovascularization and proliferative fibrosis (each feature enriched in major pathologic responders versus nonresponders, P < 0.05). This distinct constellation of histologic findings was not identified in any pretreatment specimens. Histopathologic features of the regression bed were used to develop 'Immune-Related Pathologic Response Criteria' (irPRC), and these criteria were shown to be reproducible amongst pathologists. Specifically, %irRVT had improved interobserver consistency compared with %cRVT [median per-case %RVT variability 5% (0%-29%) versus 10% (0%-58%), P = 0.007] and a twofold decrease in median standard deviation across pathologists within a sample (4.6 versus 2.2, P = 0.002). Conclusions: irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy218

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med, 378, 1976, 10.1056/NEJMoa1716078 · DOI · Paper page

Cited by

See all 593

Metadata

Authors
Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., Gabrielson, E., Askin, F. B., Niknafs, N., Smith, K. N., Velez, M. J., Sauter, J. L., Isbell, J. M., Jones, D. R., Battafarano, R. J., Yang, S. C., Danilova, L., Wolchok, J. D., Topalian, S. L., Velculescu, V. E., Pardoll, D. M., Brahmer, J. R., Hellmann, M. D., Chaft, J. E., Cimino-Mathews, A., & Taube, J. M.
Affiliations
  • Johns Hopkins University (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Taube, J.M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-08
Volume
29
Issue
8
Pages
1853-1860
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2867613812
Cited by
592
References
20
Citations by year
2026: 80 · 2025: 97 · 2024: 91 · 2023: 101 · 2022: 82 · 2021: 58 · 2020: 55 · 2019: 20 · 2018: 7
FWCI
13.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sidney Kimmel Cancer Center (P30 CA006973, CA180950)
  • National Cancer Institute (R01 CA142779)
  • NIH (T32 CA193145, P30 CA008748)
  • LCFA (#125133)
  • KNS (CA121113)
  • VEV
  • LUNGevity Foundation
  • V Foundation
  • MacMillan Foundation
  • International Association for the Study of Lung Cancer
  • Memorial Sloan Kettering Cancer Center
  • Research Institute Cancer Immunology Translational Cancer Research (SU2C-AACR-DT1012)
  • American Association for Cancer Research
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
non-small cell lung cancer, residual viable tumor, nivolumab, tumor-infiltrating lymphocytes, tertiary lymphoid structures, cholesterol clefts, neovascularization, interobserver reproducibility, immunotherapy response assessment
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Feasibility Studies, Humans, Lung, Lung Neoplasms, Pneumonectomy, Prognosis, Reproducibility of Results, Treatment Outcome, Neoplasm, Residual, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). https://app.cochat.ai/papers/10.1093/annonc/mdy218
The paper
Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., Gabrielson, E., Askin, F. B., Niknafs, N., Smith, K. N., Velez, M. J., Sauter, J. L., Isbell, J. M., Jones, D. R., Battafarano, R. J., . . . Taube, J. M. (2018). Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of Oncology. https://doi.org/10.1093/annonc/mdy218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.